Shareholders where promised better communication, do you believe that the team has delivered on this promise? And if not who is accountable and what will they do to improve the communication?
Will the leadership team review their remuneration and realign it to the current market position?
With Vaxinia we saw a CR and very promising results at low to medium doses, in your view does the data improve with increased dosage? If the data indicates that it does not impact the effectiveness over a low to medium dose will that be communicated back to shareholders and what would that mean for the ongoing approach to the Vaxinia and OnCarlytics trials?
Shareholders where promised better communication, do you believe...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.001(7.69%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.2¢ | $267.3K | 20.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 788815 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 13241534 | 29 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |